European Association for the Study of Diabetes

Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes

Retrieved on: 
목요일, 6월 8, 2023
Aviation, European Association for the Study of Diabetes, Therapy, SAN, Pharmaceutical industry, Tobacco, Diabetes

SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc .

Key Points: 
  • SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc .
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion at the 59th annual meeting of the European Association for the Study of Diabetes, to be held October 2–6, 2023 in Hamburg, Germany.
  • Details of the presentations are as follows:

Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023

Retrieved on: 
수요일, 6월 7, 2023
Steatosis, Abstract, Insulin resistance, EASL, Histology, European Association for the Study of the Liver, NASH, CAP, PPAR, Diabetes, Jugular venous pressure, Liver disease, Biomarker, Inflammation, Fibrosis, Euronext Paris, GW501516, Metabolism, Patient, Splanchnic, Fatty liver disease, ALT, NAFLD, European Association for the Study of Diabetes, Adiponectin, Isotope, Medical imaging, Pharmaceutical industry, Silviculture, Liver, Rosiglitazone, Fenofibrate

the reduction of the increased portal pressure and improvement of steatosis in a rat model of early NAFLD following a 4-week lanifibranor treatment.

Key Points: 
  • the reduction of the increased portal pressure and improvement of steatosis in a rat model of early NAFLD following a 4-week lanifibranor treatment.
  • the greater reduction of the increased portal pressure associated with early NAFLD following lanifibranor treatment compared to the PPAR agonists α, δ  or γ individually.
  • The hepatic  steatosis was measured by histological grading and by imaging using Controlled Attenuation Parameter (“CAPTM”) Fibroscan®.
  • The fourth abstract evaluates the effect of lanifibranor on portal pressure, endothelial dysfunction and liver histology in a rat model of early NAFLD.

Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes

Retrieved on: 
월요일, 6월 5, 2023
Obesity, Type 2 diabetes, American Diabetes Association, Connective tissue, Weight loss, Pharmacokinetics, European Association for the Study of Diabetes, Metabolism, DSM-IV codes, Patient, PTP1B, IND, Safety, Pharmaceutical industry, Diabetes

The study is a first-in-human, single center, single dose, randomized, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered ENT-03 in development for the treatment of obesity and Type 2 diabetes.

Key Points: 
  • The study is a first-in-human, single center, single dose, randomized, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered ENT-03 in development for the treatment of obesity and Type 2 diabetes.
  • It will be conducted in the U.S. and will enroll approximately 49 patients, with results expected in the fourth quarter of 2023.
  • The first five cohorts will consist of obese but otherwise healthy volunteers and the last two cohorts will involve obese subjects with Type 2 diabetes.
  • The first compound, ENT-01, has completed a successful randomized Phase 2b study in patients with Parkinson’s disease ( https://www.acpjournals.org/doi/10.7326/M22-1438 ).

ENDRA Life Sciences Reports First Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
월요일, 5월 15, 2023
Health, Science, Radiology, Research, Health Technology, Fatty liver disease, EASL, International, De novo, Marketing, Data collection, Temperature, Sale, Congress, MRI, PIN, Non-alcoholic fatty liver disease, NDRA, NAFLD, European Association for the Study of Diabetes, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Medical imaging, Dietary supplement, Security (finance), Liver, Diabetes

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2023 and provided a business update.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2023 and provided a business update.
  • The data will also be used to support commercialization of the TAEUS liver device in Europe and, after FDA clearance, in the U.S.
  • The De Novo pathway is reserved for novel technologies and should assist ENDRA in achieving the strongest market position with TAEUS-optimized claims.
  • In the first quarter, ENDRA participated in the Francophone Society of Diabetes annual meeting.

Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

Retrieved on: 
월요일, 2월 6, 2023
Society, ASH, OLE, CNTA, Greenwich Mean Time, Haemophilia, Patient, APC, Person, PWH, European Association for the Study of Diabetes, Pharmaceutical industry

The Company recently announced positive results from the Phase 2a OLE at the 64th American Society of Hematology (ASH) Annual Meeting.

Key Points: 
  • The Company recently announced positive results from the Phase 2a OLE at the 64th American Society of Hematology (ASH) Annual Meeting.
  • Abstract Title: SerpinPC in persons with severe hemophilia (PwH): Updated results from a multi-center, multi-part, first-in-human study.
  • Date / Time of presentation: Friday, February 10, 2023, 1:20 p.m. GMT Time.
  • A copy of the presentation will be made available on the Company’s website after the formal presentation.

Abbott's FreeStyle Libre® 3 Integrated with Automated Insulin Delivery System mylife™ Loop in Germany

Retrieved on: 
수요일, 12월 21, 2022
Consensus, FreeStyle, NYSE, AID, International Diabetes Center at Park Nicollet, Loop, Continuous glucose monitor, FX, JDRF, American Diabetes Association, Life, T1D, European Association for the Study of Diabetes, Disability, Multimedia, Nutritional immunology, Insulin, Medical device, Pharmaceutical industry, Diabetes

This automated insulin delivery system (AID) solution is now available in Germany and will be available in additional European countries beginning in 2023.

Key Points: 
  • This automated insulin delivery system (AID) solution is now available in Germany and will be available in additional European countries beginning in 2023.
  • Nearly five healthy years could be restored if they had access to devices that monitor glucose and automate insulin delivery.
  • "Technological innovations, like automated insulin delivery systems, can ease some of that uncertainty by continuously monitoring a person's glucose levels and delivering the right insulin dosage, which can ultimately improve time in range.
  • In addition to partnering with Ypsomed and CamDiab, Abbott is working to make the FreeStyle Libre platform interoperable with other leading insulin delivery systems.

VinFuture Announces the Event Series of VinFuture Sci-Tech Week 2022

Retrieved on: 
수요일, 12월 14, 2022
Lithium, Elan d'or Award Special Prize, Nobel Prize, Life, Innovation, Hanoi Opera House, Student, Science, Discovery, Bachelor of Engineering, US, Zhejiang Sci-Tech University, Invention, Millennium Technology Prize, University of California, Davis, Korean House for International Solidarity, Female, Education, STEM, Paganini Competition, European Association for the Study of Diabetes, Stanford University, Perelman School of Medicine at the University of Pennsylvania, University of Cambridge, CNN, Argonne National Laboratory, Convention center, University, Agriculture, University of Pennsylvania, Video game, Pharmaceutical industry, Creative industries, Powder metallurgy, Euronews, Physics

Hanoi, Vietnam--(Newsfile Corp. - December 13, 2022) - VinFuture Foundation officially announces the agenda of the second VinFuture Sci-Tech Week, taking place between December 17-21, 2022 in Hanoi.

Key Points: 
  • Hanoi, Vietnam--(Newsfile Corp. - December 13, 2022) - VinFuture Foundation officially announces the agenda of the second VinFuture Sci-Tech Week, taking place between December 17-21, 2022 in Hanoi.
  • Taking place over five days, the event series includes: "Conversation with the VinFuture Prize Council and Pre-screening Committee"; "Innovate Today, Create Tomorrow" Inspirational Talk Series; "Science for Life Symposium"; "VinFuture Prize Award Ceremony"; and "Talk Future: A dialogue with the 2022 VinFuture Prize Laureates".
  • The main event of the week is the 2022 VinFuture Prize Award Ceremony - Reviving and Reshaping - held in the evening of December 20, 2022, at the Hanoi Opera House to honor the next VinFuture laureates.
  • Closing the VinFuture Sci-Tech Week is Talk Future: A dialogue with the 2022 VinFuture Prize Laureates, which will take place throughout the day on December 21, 2022.

Vingroup: VinFuture announces the event series of VinFuture Sci-Tech Week 2022

Retrieved on: 
일요일, 12월 18, 2022
Lithium, Elan d'or Award Special Prize, Nobel Prize, Life, Hanoi Opera House, Create, Student, NEWS, European Association for the Study of Diabetes, Discovery, Bachelor of Engineering, US, Zhejiang Sci-Tech University, Science, Invention, Millennium Technology Prize, University of California, Davis, Korean House for International Solidarity, Female, Education, STEM, Paganini Competition, Perelman School of Medicine at the University of Pennsylvania, Stanford University, University of Cambridge, CNN, Clean technology, Argonne National Laboratory, Convention center, University, Agriculture, University of Pennsylvania, Video game, Pharmaceutical industry, Powder metallurgy, Security (finance), Euronews, Physics

HA NOI, VIETNAM - Media OutReach - 13 December 2022 – VinFuture Foundation officially announces the agenda of the second VinFuture Sci-Tech Week, taking place between December 17–21, 2022 in Hanoi.

Key Points: 
  • HA NOI, VIETNAM - Media OutReach - 13 December 2022 – VinFuture Foundation officially announces the agenda of the second VinFuture Sci-Tech Week, taking place between December 17–21, 2022 in Hanoi.
  • Taking place over five days, the event series includes: “Conversation with the VinFuture Prize Council and Pre-screening Committee”; “Innovate Today, Create Tomorrow” Inspirational Talk Series; “Science for Life Symposium”; “VinFuture Prize Award Ceremony”; and “Talk Future: A dialogue with the 2022 VinFuture Prize Laureates”.
  • The main event of the week is the 2022 VinFuture Prize Award Ceremony – Reviving and Reshaping – held in the evening of December 20, 2022, at the Hanoi Opera House to honor the next VinFuture laureates.
  • Closing the VinFuture Sci-Tech Week is Talk Future: A dialogue with the 2022 VinFuture Prize Laureates, which will take place throughout the day on December 21, 2022.

New International Consensus on CGM Clinical Trial Metrics Aims to Spur Diabetes Treatment Advances

Retrieved on: 
화요일, 12월 6, 2022
Online, American Diabetes Association, Ljubljana University Medical Centre, International Conference on Population and Development, JDRF, Food, European Association for the Study of Diabetes, Human, Endocrinology, Conference, International Society for Pediatric and Adolescent Diabetes, DCCT, International Society, ATTD, Israel Advanced Technology Industries, Patient, Science, CGM, Collection, CGMS-A, Research, Adolescence, Treatment, Disease, Blood, Obesity, Quality of life, US Food Sovereignty Alliance, European Medicines Agency, Paper, News, The Lancet, TIR, SAN, Pharmaceutical industry, Cryptocurrency, Diabetes

The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.

Key Points: 
  • The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.
  • The article, "Continuous glucose monitoring and metrics for clinical trials: an international consensus statement," is available here .
  • "Standardizing the use of CGM data in clinical trials of diabetes therapies will help ensure that the next generation of treatments are focused on increasing patients' TIR and, therefore, quality of life."
  • As such, earlier this year, the diaTribe Foundation, ATTD, and the Time in Range Coalition convened a group of international experts to discuss and reach consensus on the role of CGMs and CGM-derived metrics in clinical trials for diabetes treatment.

New International Consensus on CGM Clinical Trial Metrics Aims to Spur Diabetes Treatment Advances

Retrieved on: 
화요일, 12월 6, 2022
Online, American Diabetes Association, Ljubljana University Medical Centre, International Conference on Population and Development, JDRF, Food, European Association for the Study of Diabetes, Human, Endocrinology, Conference, International Society for Pediatric and Adolescent Diabetes, DCCT, International Society, ATTD, Israel Advanced Technology Industries, Patient, Science, CGM, Collection, CGMS-A, Research, Adolescence, Treatment, Disease, Blood, Obesity, Quality of life, US Food Sovereignty Alliance, European Medicines Agency, Paper, News, Multimedia, The Lancet, TIR, SAN, Pharmaceutical industry, Cryptocurrency, Diabetes

The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.

Key Points: 
  • The groundbreaking consensus statement, endorsed by numerous leading US and international diabetes organizations, including the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists, DiabetesIndia, European Association for the Study of Diabetes, International Society for Pediatric and Adolescent Diabetes, Japan Diabetes Society, and JDRF, was published in The Lancet Diabetes & Endocrinology on December 6, 2022.
  • The article, "Continuous glucose monitoring and metrics for clinical trials: an international consensus statement," is available here .
  • "Standardizing the use of CGM data in clinical trials of diabetes therapies will help ensure that the next generation of treatments are focused on increasing patients' TIR and, therefore, quality of life."
  • As such, earlier this year, the diaTribe Foundation, ATTD, and the Time in Range Coalition convened a group of international experts to discuss and reach consensus on the role of CGMs and CGM-derived metrics in clinical trials for diabetes treatment.